News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
Content Sharing
SBP GROUP Forms Exclusive Strategic Collaboration with GlaxoSmithKline to Accelerate Mainland Launch of bepirovirsen
SBP GROUP (01177.HK) announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the Company, entered into an exclusive strategic collaboration with Gla...
Reset
Send
The window will close in 5 seconds
SBP GROUP Forms Exclusive Strategic Collaboration with GlaxoSmithKline to Accelerate Mainland Launch of bepirovirsen
Close
Recommend
22
Positive
45
Negative
15
 
 

SBP GROUP (01177.HK)  -0.060 (-1.136%)    Short selling $40.76M; Ratio 19.291%   announced that Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a subsidiary of the Company, entered into an exclusive strategic collaboration with GlaxoSmithKline (GSK) to accelerate bepirovirsen in mainland China at launch.

Under the agreement, CTTQ will be responsible for importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China. Revenue generated from product sales in China is expected to be recognised by CTTQ. GSK will remain the marketing authorisation holder (MAH) and retain responsibility for regulatory, quality, pharmacovigilance and global medical strategy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.